Drug Profile
Racemetyrosine - Syros Pharmaceuticals
Alternative Names: a-methylparatyrosine; Alpha metyrosine; D/L-alpha metyrosine; SM-88; SM-88i; SM-88nLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Tyme Technologies
- Developer Georgetown University; Pancreatic Cancer Action Network; Syros Pharmaceuticals; The Joseph Ahmed Foundation
- Class Amino acids; Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Immunomodulators; Protein synthesis inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Ewing's sarcoma; Prostate cancer
- Preclinical Cancer
- No development reported Glioma; Osteosarcoma
- Discontinued Pancreatic cancer
Most Recent Events
- 18 Jan 2024 Efficacy and adverse events data from a phase III Precision Promise (PrP) Bayesian platform trial in Pancreatic cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 10 Feb 2023 Tyme terminates phase II trial in Breast Cancer in the US (PO, Capsule) (NCT04720664)
- 16 Sep 2022 Syros Pharmaceuticals acquires Racemetyrosine from Tyme Technologies